… is unknown but postulated to be related to inhibition of tissue factor activity, a natural
anticoagulant. Nonetheless, both agents have been shown to restore and potentiate thrombin …

… anticoagulation with dabigatran, reversal of anticoagulation … -inhibitor-associated, non-traumatic
ICH and evaluated efficacy and safety of reversal the FXa inhibitors with andexanet alfa …

… of a 91 year old female that developed bilateral pulmonary embolism 11 days after receiving
andexanet alfa; the patient had not been re-anticoagulated after receiving treatment with …

… specific FXa inhibitor reversal agent, recombinant FXa (Andexanet alfa), … anticoagulation
reversal is required for patients with uncontrolled or life-threatening bleeding [8]. Andexanet alfa …

… -PCC or andexanet alfa for patients with FXa-inhibitor-associated … andexanet alfa for ongoing
bleeding complicating surgical completion when other therapeutic anticoagulation reversal …

… Despite the obvious mechanistic relation between the reversal of anticoagulation, it is
important to consider the very elevated risk of embolism in our cohort, particularly considering the …

… Andexanet alfa (AA) is a recombinant factor Xa competing for binding with factor Xa
inhibitors, thereby reversing their anticoagulation effects. Since 2019, it has been approved for …

… Anticoagulation reversal with andexanet alfa was deemed effective (excellent [n = 3], good
[n = 7]) in 10 (47.6%) patients, and poor in 11 patients (52.4%). Eight (38.1%) patients died, of …

… factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent
that reverses the effects of factor … , 9 and rapid reversal of anticoagulation could reduce the …

… andexanet alfa or prothrombin complex concentrate to reverse factor Xa inhibitor-associated …
, and cost-effectiveness make direct oral anticoagulants and factor Xa (FXa) inhibitors (FXaIs…